---
title: "Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292904153.md"
description: "Grifols has initiated dosing for the first patients in two Phase 3 trials aimed at expanding U.S. market approval for its flagship immunoglobulin therapies, GAMUNEX-C and XEMBIFY. The global healthcare company, listed on NASDAQ under GRFS, seeks to broaden indications for these plasma-derived medicines."
datetime: "2026-07-16T12:00:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292904153.md)
  - [en](https://longbridge.com/en/news/292904153.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292904153.md)
---

# Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

In Barcelona, Spain, on July 16, 2026, a major global healthcare company, Grifols, disclosed that they have begun dosing the initial patients in two distinct Phase 3 trials. The objective of these trials is to broaden the U.S. market approval for their key immunoglobulin medications. These include GAMUNEX ® -C, an intravenous immunoglobulin (IVIg), and XEMBIFY ®, a subcutaneous immunoglobulin (SCIg). Grifols is recognized as a top producer of plasma-derived medicines and is listed on the MCE under tickers GRF and GRF.P, as well as on the NASDAQ under ticker GRFS.

### Related Stocks

- [GRFS.US](https://longbridge.com/en/quote/GRFS.US.md)

## Related News & Research

- [Grifols Reshapes Board and Committee Leadership After Director Resignation](https://longbridge.com/en/news/294387432.md)
- [FOXO unit Vector BioSource agrees to buy four Grifols blood collection centers for $3.5 million plus up to $1 million earnout](https://longbridge.com/en/news/293970318.md)
- [Bloom Energy Says a Four-Year Backlog Isn't a Trophy. It's a Confession.](https://longbridge.com/en/news/294216903.md)
- [Moleculin Biotech prices offering with warrants for 37,130,001 shares at $0.75 exercise price](https://longbridge.com/en/news/294525518.md)
- [EXCLUSIVE: Webull Just Made 'Smart Money' Bond Strategy Available For $500](https://longbridge.com/en/news/293993811.md)